Amgen Inc. (NASDAQ:AMGN) Shares Sold by AMG National Trust Bank

AMG National Trust Bank cut its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 61.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,157 shares of the medical research company's stock after selling 16,102 shares during the quarter. AMG National Trust Bank's holdings in Amgen were worth $3,273,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of AMGN. Capital International Investors grew its holdings in Amgen by 547.8% in the first quarter. Capital International Investors now owns 7,005,269 shares of the medical research company's stock worth $1,991,738,000 after purchasing an additional 5,923,915 shares during the period. Pathway Financial Advisers LLC raised its stake in Amgen by 33,125.4% during the third quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company's stock valued at $1,437,115,000 after buying an additional 4,446,757 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Amgen by 6.4% in the second quarter. Dimensional Fund Advisors LP now owns 2,701,631 shares of the medical research company's stock worth $844,137,000 after acquiring an additional 162,223 shares in the last quarter. International Assets Investment Management LLC grew its stake in shares of Amgen by 6,812.4% in the third quarter. International Assets Investment Management LLC now owns 2,523,387 shares of the medical research company's stock worth $8,130,610,000 after acquiring an additional 2,486,882 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of Amgen by 137.1% in the first quarter. Janus Henderson Group PLC now owns 2,381,133 shares of the medical research company's stock worth $676,984,000 after acquiring an additional 1,377,007 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of NASDAQ AMGN traded up $1.24 during mid-day trading on Tuesday, hitting $280.00. 2,071,244 shares of the company's stock traded hands, compared to its average volume of 2,455,147. The company has a market capitalization of $150.51 billion, a P/E ratio of 35.69, a PEG ratio of 2.53 and a beta of 0.60. Amgen Inc. has a 1 year low of $260.52 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The company's 50-day moving average is $319.90 and its two-hundred day moving average is $318.65.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts' consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to analysts' expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm's revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the previous year, the company earned $4.96 EPS. On average, equities analysts anticipate that Amgen Inc. will post 19.51 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be paid a dividend of $2.25 per share. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 3.21%. Amgen's dividend payout ratio is currently 115.24%.

Analyst Upgrades and Downgrades

AMGN has been the topic of several analyst reports. Barclays upped their target price on shares of Amgen from $300.00 to $315.00 and gave the stock an "equal weight" rating in a research note on Monday, October 7th. StockNews.com upgraded Amgen from a "buy" rating to a "strong-buy" rating in a research note on Friday, November 1st. Wolfe Research started coverage on Amgen in a research note on Friday. They issued a "peer perform" rating for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $305.00 target price (down previously from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Amgen has a consensus rating of "Moderate Buy" and an average price target of $333.57.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.